Clinical trials: Bevacizumab
Non-small-cell Lung Cancer
Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer
This trial will evaluate the efficacy and safety of pemetrexed and bevacizumab combination in patients with pretreated, advanced non small cell lung cancer (NSCLC).
- Trial name
- NCT00741221
- Testing
- Pemetrexed, Bevacizumab
- Where
- 10 sites in Greece
- Volunteers
- 50 people
- Sponsor
- Hellenic Oncology Research Group
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs.
- Conditions
- Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma
- Trial name
- NCT04739800
- Testing
- Biospecimen Collection, Cediranib Maleate, Computed Tomography
- Where
- 391 sites in United States, Puerto Rico
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with urothelial cancer who have progressed on or after chemotherapy and anti- PD-1/PD-L1 therapy.
- Trial name
- NCT03197571
- Testing
- avelumab, bevacizumab, capecitabine
- Sponsor
- ImmunityBio, Inc.
Cervical Cancer
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
The investigators propose to evaluate the efficacy of the combination of standard chemotherapy with bevacizumab with Pembrolizumab in women with recurrent, persistent, or metastatic cervical cancer.
- Trial name
- NCT03367871
- Testing
- Pembrolizumab, Paclitaxel, Cisplatin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Miami
Nasopharyngeal Carcinoma
PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
At present, the treatment regimen of locally advanced nasopharyngeal carcinoma still needs to be further improved, and the focus of improvement lies in "replacing cisplatin with high-efficiency and low-toxicity treatment…
- Trial name
- NCT05341193
- Testing
- Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab, Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other…
- Conditions
- Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
- Trial name
- NCT07024784
- Testing
- IMGN151, Carboplatin, Bevacizumab
- Where
- 21 sites in United States, Israel and 1 more
- Volunteers
- 377 people
- Sponsor
- AbbVie
Recurrent Respiratory Papillomatosis
Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
The aim of this study is to compare the efficacy of intralesional bevacizumab, a monoclonal antibody against vascular endothelial growth factor, versus the antiviral drug cidofovir in patients with recurrent respiratory…
- Trial name
- NCT02555800
- Testing
- Bevacizumab, Cidofovir
- Where
- Mexico
- Volunteers
- 36 people
- Sponsor
- Centro de Investigación en. Enfermedades Infecciosas, Mexico
Unresectable Metastatic Colorectal Cancer
Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment
Bevacizumab is a standard drug for metastatic colorectal cancer (mCRC) in combination with cytotoxic chemotherapy. However, inter-individual pharmacokinetic variability was observed for bevacizumab and an exposure-response…
- Trial name
- PHARBEVACOL (NCT06642844)
- Testing
- Avastin, 25 Mg/mL Intravenous Solution
- Where
- 4 sites in France
- Volunteers
- 244 people
- Sponsor
- University Hospital, Tours
Colorectal Cancer Metastatic
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
The purpose of the present study is to investigate the benefit of anti-cancer therapy administered on the basis of drug sensitivity testing. This concerns colorectal cancer patients who have previously received standard treatment.
- Trial name
- NCT03251612
- Testing
- Based on sensitivity analysis
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 90 people
- Sponsor
- Vejle Hospital
Diabetic Macular Edema
Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema
Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema
- Trial name
- ATEMD (NCT00737971)
- Testing
- Bevacizumab intravitreal, Triamcinolone, Triamcinolone + Bevacizumab
- Where
- Brazil
- Volunteers
- 142 people
- Sponsor
- Rubens Belfort Jr.
Metastatic Breast Cancer
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
The purpose of this research study is to look at the effectiveness of a combination of doxil, carboplatin and bevacizumab on metastatic breast cancer.
- Trial name
- NCT00608972
- Testing
- Doxil, Carboplatin, Bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Rutgers, The State University of New Jersey
Non-Small Cell Lung Cancer
Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC
The primary objective is to determine the progression free survival with pemetrexed, and gemcitabine plus bevacizumab as first-line chemotherapy in elderly patients with Stage IIIB/IV non-small cell lung cancer (NSCLC).
- Trial name
- NCT00517595
- Testing
- Pemetrexed and Gemcitabine plus Bevacizumab
- Where
- 10 sites in United States
- Volunteers
- 48 people
- Sponsor
- Accelerated Community Oncology Research Network
Advanced Solid Tumors
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Immune therapies work with the body's immune system to treat a number of cancers. They work with T-cells, a type of white blood cell, to target and attack specific tumors.
- Trial name
- NCT05083481
- Testing
- ASP1570, pembrolizumab, Trifluridine + Tipiracil
- Where
- 30 sites in United States, China and 4 more
- Volunteers
- 226 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Colorectal Cancer, Metastasis
Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab
It is a prospective, non-randomized, monocentric study. The purpose of the study is to assess the predictive value of VE-cadherin on the objective tumor response.
- Trial name
- AVECC (NCT01405430)
- Testing
- Bevacizumab + blood samples
- Where
- 2 sites in France
- Volunteers
- 63 people
- Sponsor
- Centre Leon Berard
Solid Cancers
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase Ib, open-label, dose-escalation study of MEGF0444A in combination with bevacizumab, and in combination with bevacizumab and paclitaxel as therapy for locally advanced or metastatic solid tumors.
- Trial name
- NCT01075464
- Testing
- MEGF0444A, bevacizumab, paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Genentech, Inc.
Age Related Macular Degeneration
Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration
The purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with neovascular age related…
- Trial name
- NCT00347399
- Testing
- bevacizumab intravitreal injection, verteporfin photodynamic therapy
- Where
- Mexico
- Volunteers
- 25 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Glioma
A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma
To determine the safety and efficacy of surgical resection with Gliadel® 3.85% wafer implantation, followed by concomitant limited field radiation therapy and temozolomide, followed by dose dense temozolomide and bevacizumab in…
- Trial name
- KARE004 (NCT00660621)
- Testing
- Temozolomide and Bevacizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Kentuckiana Cancer Institute
Glaucoma, Rubeosis Iridis
Intraocular Bevacizumab (Avastin) for Rubeosis Iridis
Bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) is an anti-VEGF recombinant humanized monoclonal IgG1 antibody used to treat colorectal cancers.
- Trial name
- NCT00557232
- Testing
- bevacizumab
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Instituto de Olhos de Goiania
Ovarian Cancer
Autophagy Maintenance (AUTOMAIN)
This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and nelfinavir mesylate (NFV) will benefit ovarian cancer…
- Trial name
- NCT06971744
- Testing
- Hydroxychloroquine, Nelfinavir, Bevacizumab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Medical University of South Carolina
Refractory Metastatic Colorectal Cancer
Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial
This study is an investigator-initiated, prospective, multicenter, randomized, controlled, open-label, non-inferiority trial designed to evaluate the efficacy and safety of trifluridine/tipiracil plus fruquintinib versus…
- Trial name
- NCT07261709
- Testing
- Trifluridine/tipiracil plus fruquintinib, trifluridine/tipiracil plus bevacizumab
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University